3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study Journal Article
| Authors: | Cheung, N. K. V.; Kushner, B. H.; Yeh, S. D. J.; Larson, S. M. |
| Article Title: | 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study |
| Abstract: | 3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside G(D2). In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79- 130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation. |
| Keywords: | adolescent; cancer survival; child; unclassified drug; clinical trial; disease course; cisplatin; doxorubicin; hypertension; cancer staging; dacarbazine; pain; phase 2 clinical trial; blood toxicity; cyclophosphamide; vincristine; antineoplastic activity; drug potency; drug effect; monoclonal antibody; fever; hypotension; infant; neuroblastoma; ganglioside gd2; urticaria; intravenous drug administration; monoclonal antibody 3f8; respiratory distress; epipodophyllotoxin; phase ii study; human; priority journal; article; 3f8 monoclonal antibody |
| Journal Title: | International Journal of Oncology |
| Volume: | 12 |
| Issue: | 6 |
| ISSN: | 1019-6439 |
| Publisher: | Spandidos Publications |
| Date Published: | 1998-06-01 |
| Start Page: | 1299 |
| End Page: | 1306 |
| Language: | English |
| PUBMED: | 9592190 |
| PROVIDER: | scopus |
| DOI: | 10.3892/ijo.12.6.1299 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 12 December 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work